Catheter Precision, Inc. announced on April 23, 2025, that it has signed a definitive agreement to acquire assets of Cardionomic, Inc. These assets are related to its Cardiac Pulmonary Nerve Stimulation (CPNS) System, a late-stage treatment in development for acute decompensated heart failure.
The acquisition will be conducted through Cardionomix, Inc., a newly formed, 82% owned subsidiary of Catheter Precision. Initial clinical studies for the CPNS System have been completed and showed significant positive results.
This strategic move represents an expansion of Catheter Precision's product pipeline into the heart failure treatment market. The acquisition of these assets diversifies the company's therapeutic focus and offers a potential new revenue stream in the future.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.